Sensus Healthcare (NASDAQ:SRTS) PT Raised to $10.00

Sensus Healthcare (NASDAQ:SRTS) had its price objective raised by HC Wainwright from $8.00 to $10.00 in a note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 88.68% from the company’s current price. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.15 EPS, Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.22 EPS and FY2025 earnings at $0.47 EPS.

Separately, Maxim Group raised their price target on Sensus Healthcare from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, May 10th.

Sensus Healthcare Stock Down 1.9 %

NASDAQ:SRTS opened at $5.30 on Monday. Sensus Healthcare has a 52-week low of $1.79 and a 52-week high of $5.85. The stock has a fifty day simple moving average of $3.71 and a 200-day simple moving average of $3.20. The company has a market capitalization of $86.89 million, a PE ratio of 18.28 and a beta of 0.92.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, May 9th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.18. Sensus Healthcare had a net margin of 14.70% and a return on equity of 10.01%. The company had revenue of $10.66 million during the quarter, compared to analysts’ expectations of $4.33 million. During the same quarter in the previous year, the business posted ($0.12) earnings per share. As a group, equities analysts anticipate that Sensus Healthcare will post 0.08 earnings per share for the current year.

Institutional Trading of Sensus Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of SRTS. Hillsdale Investment Management Inc. purchased a new stake in shares of Sensus Healthcare in the first quarter valued at $155,000. Creekmur Asset Management LLC purchased a new position in shares of Sensus Healthcare during the 4th quarter worth about $83,000. Sachetta LLC purchased a new position in shares of Sensus Healthcare during the 4th quarter worth about $247,000. Finally, Perritt Capital Management Inc. boosted its position in shares of Sensus Healthcare by 5.0% in the third quarter. Perritt Capital Management Inc. now owns 105,586 shares of the company’s stock worth $292,000 after acquiring an additional 5,000 shares during the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.